KELLI DEWITT WHITEHEAD, RN, MS, ARNP

Transcription

1 CIRRICULUM VITAE KELLI DEWITT WHITEHEAD, RN, MS, ARNP Associated Urologist, PA 341 Wheatfield, Suite 180 Sunnyvale, TX EDUCATION Master of Science, Family Nurse Practitioner University of Oklahoma Bachelor of Science in Nursing University of Oklahoma PROFESSIONAL EXPERIENCE Nurse Practitioner Associated Urologist, PA and Medical-Edge, PA 2540 N. Galloway Ave. #103 Mesquite, TX Nurse Practitioner Urology Centers of Oklahoma 2349 N. Thompkins Bethany, OK Sub-Investigator Parkhurst Research Organization 2349 N. Thompkins Bethany, OK Nurse Practitioner and Clinic Coordinator UNITUS Centers for Sexual Medicine 2349 N. Thompkins Bethany, OK Sub-Investigator ntouch Research 5300 N. Grand Blvd. #300 Oklahoma City, OK present

2 Traveling School Nurse Oklahoma City Public School System 900 N. Klein Oklahoma City, OK Adjunct Faculty: Campus lab, computer lab, clinical instructor Oklahoma City Community College Oklahoma City, OK Part-Time Staff Nurse: Oncology Baptist Medical Center Oklahoma City, OK Traveling School Nurse Oklahoma City Public School System 900 N. Klein Oklahoma City, OK Staff Nurse: Neonatal Intensive Care Unit Oklahoma Children s Memorial Hospital 940 N.E. 13 th Oklahoma City, OK LICENSURE AND CERTIFICATION Family Nurse Practitioner American Nurses Credentialing Center # Registered Nurse Texas Board of Nurse Examiners License# , RX# Basic Life Support American Heart Association Registered Nurse Oklahoma Board of Nursing 1997-present 2004-present 1979-present

3 AFFILIATIONS American Urological Association The Women s Sexual Health Foundation Texas Nurse Practitioners National Association for Continence International Society for the Study of Women s Sexual Function Society of Urologic Nurses and Associates American Academy of Nurse Practitioners Sigma Theta Tau, Beta Delta Chapter 2009-present 2007-present 2005-present 2002-present 2002-present 1980-present 1997-present 1997-present HONORS Academic Achievement Award 1997 University of Oklahoma College of Nursing Outstanding Clinical Practice Award 1997 University of Oklahoma College of Nursing Sigma Theta Tau, Beta Delta Chapter 1997 Professional Nurse Traineeship Scholarship C. W. Moore Native American Scholarship EDUCATIONAL WORKSHOPS/SEMINARS SUNA Annual Symposium: Incontinence and Pelvic Floor Disorders 2009 ISSWSH Annual Meeting 2008 International Society for the Study of Women s Sexual Health 2007 Fall 2007 Coarse Female Sexual Medicine: Highlights and Developments SUNA Annual Symposium Sexuality, Intimacy, and Pelvic Floor 2007 Disorders Advanced Urodynamic Female Urology and Voiding Dysfunction 2006 Health Care Strategies for a Changing World 2006 SUNA Annual Symposium: Disorders of the Bladder, Bowel, and 2006 Pelvic Floor Year 2005 Hypertension Update 2005 Changing Face of Anemia in Dialysis Patients, Amgen 2004 Health Essentials 2004 Annual Meeting 2004 Changing the Treatment of Alzheimer s Disease in LTC 2004 Wound Healing, A Script for Success 2004 Speaker on Female Sexual Dysfunction, University of Oklahoma 6 th 2004 Annual Nurse Practitioner Conference Oklahoma Nurse Practitioners 9 th Annual Conference 2003 Speaker on Urinary Incontinence, University of Oklahoma 5 th Annual 2003 Nurse Practitioner Conference Peceptorship with Dr. Irwin Goldstein Boston University College of 2003 Medicine Existing and Alternative Treatment Options for BPH

4 Oklahoma Nurse Practitioners 8 th Annual Conference 2002 Speaker on Pessaries, University of Oklahoma 5 th Annual Nurse 2002 Practitioner Conference 32 nd Annual Society of Urologic Nurses and Associates Conference 2001 ISSWSH Female Sexual Dysfunction Forum 2000 Oklahoma State Nurse Practitioners 6 th Annual Conference 2000 Female Sexual Dysfunction Forum 2000 Fifth National Multi-Specialty Conference On Urinary Incontinence 2000 Oklahoma State Nurse Practitioners 5 th Annual Conference 1999 Advanced Concepts in Continence Care 1999 American Urological Association 99 Annual Review Course 1999 Into the Millennium, First Annual Nurse Practitioner Conference 1999 Advance Practice and Prescriptive Authority Update Men s Health Symposium 1998 Beyond Prozac, Institute for Natural Resources 1994 Introduction to Windows, Oklahoma City Community College 1994 Physical Assessment Skills for Nurses, Professional Ed. Systems 1994 Tuberculosis Update, Individualize Health Care Plans, Gangs-Violence 1994 In the Schools; Oklahoma School Nurse Organization Introduction to WordPerfect 5.1, Oklahoma City Community College 1994 Chemotherapy Administration Certification, Baptist Medical Center 1992 CPR Instructors Course, American Heart Association 1989 RESEARCH EXPERIENCE A phase 3, parallel group, randomized, double-blind, placebo controlled, multi-center trial to investigate the efficacy, tolerability and safety of XXXXX sustained release in subjects with overactive bladder syndrome A placebo controlled study evaluation the safety and efficacy of Oxybutynin Chloride 3 mg and 5 mg in women with overactive bladder A phase III, multi-national, randomized, double-blind, parallel group, placebo controlled, 24 week study to evaluate the efficacy and safety of XXXXX in women with low libido who have undergone hysterectomy and bilateral oophorectomy on concurrent estrogen replacement therapy A double-blind, placebo controlled study of urinary frequency and urgency using XXXXX, 20 mg tablets twice daily for 12 weeks followed by a 6 month open label treatment phase in patients with overactive bladder A placebo controlled, double-blind, randomized, parallel study of the efficacy and safety of XXXXX in the treatment of rapid ejaculation

5 An open label study of the long-term safety of XXXXX in the treatment of rapid ejaculation A randomized, double-blind, parallel group, placebo controlled study evaluation the efficacy, safety, and reliability of XXXXX administered for 12 weeks compared to placebo in subjects with erectile dysfunctional and a demonstrated successful first response to XXXXX A phase III, randomized, double-blind, parallel group, placebo controlled 6 month study to evaluate the efficacy and safety of XXXXX in naturally menopausal women with low libido on concurrent oral hormone replacement therapy A 6-week, double blind, placebo controlled, randomized, parallel group, multi-center, multidose, study of the efficacy and safety of XXXXX in patients with overactive bladder symptoms of increased urinary frequency, urgency, and urge incontinence A double-blind, placebo controlled, randomized study to evaluate the effect of XXXXX on nocturia in patients with symptoms of overactive bladder A randomized, double-blind, parallel group, multi-center study to investigate the time to on set the action of 20 mg of XXXXX to placebo in males with erectile dysfunction. At home onset of action study Extension study of A randomized, placebo controlled, double-blind, parallel design, phase 3 trial of the efficacy and safety of XXXXX in male patients with mild to moderate erectile dysfunction Efficacy and safety of XXXXX compared with placebo in subjects with stress urinary incontinence Double-blind, placebo controlled study of sustained release XXXXX in subjects with symptoms of overactive bladder of urgency, frequency, and urinary incontinence A phase III, double-blind, randomized, parallel, study evaluating the efficacy and safety of XXXXX sublingual (2 and 3 mg) in the treatment of male erectile dysfunction A randomized, placebo controlled, double-blind, parallel design, phase 3 trial of the efficacy and safety of XXXXX in male patients with mid to moderate erectile dysfunction A 52 week extension study to evaluate the long-term safety of XXXXX in subjects with overactive bladder A 12 week safety and efficacy study of oral XXXXX versus placebo in subjects with overactive bladder

6 A randomized, double-blind, placebo controlled, parallel group study of the efficacy and safety of XXXXX in the treatment and modification of progression of benign prostatic hyperplasia A phase 3 at home study evaluating the efficacy and safety of escalation doses of XXXXX in the treatment of patients with erectile dysfunction Quality of life in patients treated with Tolterodine (Detrol)